CD19 Universal CAR-T cells

Cell therapy

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

CD19 Universal CAR-T cells is one of 45 biologic programs targeting Systemic Lupus Erythematosus. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Systemic Lupus ErythematosusPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

328 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

9 2

Medrol

Pfizer

Phase 3

5 3

Rinvoq

AbbVie

Phase 3

3 4

Stelara

Johnson & Johnson

Phase 3

3 5

Ocrevus

Roche

Phase 3

2 6

Gazyva

Roche

Phase 3

2 7

Intrarosa

Alnylam Pharmaceuticals

Phase 3

1 8

Depo-Provera

Eli Lilly

Phase 3

—9

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

3 10

Benadryl

PParkedale

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Systemic Lupus Erythematosus

NCT06691152

Q4 2027

Phase 1/2Recruiting

Systemic Lupus Erythematosus

NCT06106893

Clinical

Trials by Indication[1]

Systemic Lupus Erythematosus2 trials

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1/2·NCT06106893·15 enrolled

Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus

Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1·NCT06691152·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CD19 Universal CAR-T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD19 Universal CAR-T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD19 Universal CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Union Hospital, Tongji Medical College, Huazhong University of Science and Technology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Company: UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

CD19 Universal CAR-T cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Trials by Indication[1]

Systemic Lupus Erythematosus2 trials

References

Drug Info

Quick Facts

Related News